North America Small Molecule Contract Development and Manufacturing Organization (CDMO) Market 2021-2031 by Product Type (API, FDF), Service Type (Preclinical, Clinical, Commercial), Customer Type (Pharmaceutical Firms, Biotechnology Firms), Therapeutic Area (Infectious Diseases, Oncology, Ophthalmology, Cardiovascular Disorders, Central Nervous System, Respiratory Disorders, Metabolic Diseases), and Country: Trend Forecast and Growth Opportunity
North America small molecule contract development and manufacturing organization (CDMO) market is projected to grow by 5.3%
- Bonafide Trust
- 31-12-2022
- Pages : 103
- Figures : 48
- Tables : 24
- Region : North America
- Category : Lifescience
- Healthcare
North America small molecule contract development and manufacturing organization (CDMO) market is projected to grow by 5.3% annually in the forecast period and reach $ 42,793.3 million by 2031, driven by the increasing demand for small molecule medicines and therapies, a rising demand for cost control in drug development, the increasing incidence of disease, and rising healthcare expenditures. Highlighted with 24 tables and 48 figures, this 103-page report “North America Small Molecule Contract Development and Manufacturing Organization (CDMO) Market 2021-2031 by Product Type (API, FDF), Service Type (Preclinical, Clinical, Commercial), Customer Type (Pharmaceutical Firms, Biotechnology Firms), Therapeutic Area (Infectious Diseases, Oncology, Ophthalmology, Cardiovascular Disorders, Central Nervous System, Respiratory Disorders, Metabolic Diseases), and Country: Trend Forecast and Growth Opportunity” is based on a comprehensive research of the entire North America small molecule contract development and manufacturing organization (CDMO) market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2019-2021 and provides forecast from 2022 till 2031 with 2021 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.) In-depth qualitative analyses include identification and investigation of the following aspects: • Market Structure • Growth Drivers • Restraints and Challenges • Emerging Product Trends & Market Opportunities • Porter’s Fiver Forces The trend and outlook of North America market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19 and Russia-Ukraine conflict. The balanced (most likely) projection is used to quantify North America small molecule contract development and manufacturing organization (CDMO) market in every aspect of the classification from perspectives of Product Type, Service Type, Customer Type, Therapeutic Area, and Country.
What's Inside a Bonafide Research`s industry report?
Asia-Pacific dominates the market and is the largest and fastest-growing market in the animal growth promoters industry globally
Download SampleBased on Product Type, the North America market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section. • Active Pharmaceutical Ingredients (API) o Branded Drugs o Generic Drugs • Finished Dosage Formulations (FDF) o Oral Solid Drugs o Injectable Drugs o Semi-solid or Liquid Drugs o Other FDFs Based on Service Type, the North America market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section. • Preclinical Use • Clinical Use o Phase I o Phase II o Phase III o Phase IV • Commercial Use By Customer Type, the North America market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section. • Pharmaceutical Firms • Biotechnology Firms
By Therapeutic Area, the North America market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section. • Infectious Diseases • Oncology • Ophthalmology • Cardiovascular Disorders • Central Nervous System • Respiratory Disorders • Metabolic Diseases • Other Therapeutic Areas Geographically, the following national/local markets are fully investigated: • U.S. • Canada • Mexico For each key country, detailed analysis and data for annual revenue ($ mn) are available for 2021-2031. The breakdown of national markets by Product Type, Service Type and Therapeutic Area over the forecast years are also included. The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players. Selected Key Players: Boehringer Ingelheim Cambrex Corporation Catalent Cipla Covance Inc. Lonza Group Ltd. Medley Pharmaceuticals NatcoPharma Patheon (Thermo Fisher Scientific, Inc.) Piramal Pharma Solutions RedHillBiopharma Siegfried Holding AG STA Pharmaceutical Sun Pharmaceutical Teva (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
Table of Contents
- 1 Introduction 7
- 1.1 Industry Definition and Research Scope 7
- 1.1.1 Industry Definition 7
- 1.1.2 Research Scope 8
- 1.2 Research Methodology 11
- 1.2.1 Overview of Market Research Methodology 11
- 1.2.2 Market Assumption 12
- 1.2.3 Secondary Data 12
- 1.2.4 Primary Data 12
- 1.2.5 Data Filtration and Model Design 13
- 1.2.6 Market Size/Share Estimation 14
- 1.2.7 Research Limitations 15
- 1.3 Executive Summary 16
- 2 Market Overview and Dynamics 18
- 2.1 Market Size and Forecast 18
- 2.1.1 Impact of COVID-19 on World Economy 19
- 2.1.2 Impact of COVID-19 on the Market 21
- 2.2 Major Growth Drivers 23
- 2.3 Market Restraints and Challenges 27
- 2.4 Emerging Opportunities and Market Trends 30
- 2.5 Porter’s Fiver Forces Analysis 34
- 3 Segmentation of North America Market by Product Type 38
- 3.1 Market Overview by Product Type 38
- 3.2 Active Pharmaceutical Ingredients (API) 40
- 3.2.1 Branded Drugs 41
- 3.2.2 Generic Drugs 42
- 3.3 Finished Dosage Formulations (FDF) 43
- 3.3.1 Oral Solid Drugs 45
- 3.3.2 Injectable Drugs 46
- 3.3.3 Semi-solid or Liquid Drugs 47
- 3.3.4 Other FDFs 48
- 4 Segmentation of North America Market by Service Type 49
- 4.1 Market Overview by Service Type 49
- 4.2 Preclinical Use 51
- 4.3 Clinical Use 52
- 4.3.1 Phase I 54
- 4.3.2 Phase II 55
- 4.3.3 Phase III 56
- 4.3.4 Phase IV 57
- 4.4 Commercial Use 58
- 5 Segmentation of North America Market by Customer Type 59
- 5.1 Market Overview by Customer Type 59
- 5.2 Pharmaceutical Firms 61
- 5.3 Biotechnology Firms 62
- 6 Segmentation of North America Market by Therapeutic Area 63
- 6.1 Market Overview by Therapeutic Area 63
- 6.2 Infectious Diseases 65
- 6.3 Oncology 66
- 6.4 Ophthalmology 67
- 6.5 Cardiovascular Disorders 68
- 6.6 Central Nervous System 69
- 6.7 Respiratory Disorders 70
- 6.8 Metabolic Diseases 71
- 6.9 Other Therapeutic Areas 72
- 7 North America Market 2021-2031 by Country 73
- 7.1 Overview of North America Market 73
- 7.2 U.S. 76
- 7.3 Canada 79
- 7.4 Mexico 81
- 8 Competitive Landscape 83
- 8.1 Overview of Key Vendors 83
- 8.2 New Product Launch, Partnership, Investment, and M&A 86
- 8.3 Company Profiles 87
- Boehringer Ingelheim 87
- Cambrex Corporation 89
- Catalent 90
- Cipla 91
- Covance Inc. 92
- Lonza Group Ltd. 93
- Medley Pharmaceuticals 94
- NatcoPharma 95
- Patheon (Thermo Fisher Scientific, Inc.) 96
- Piramal Pharma Solutions 97
- RedHillBiopharma 98
- Siegfried Holding AG 99
- STA Pharmaceutical 100
- Sun Pharmaceutical 101
- Teva 102
- RELATED REPORTS 103
Figure 1. Research Method Flow Chart 11
Figure 2. Bottom-up Approach and Top-down Approach for Market Estimation 14
Figure 3. North America Market Forecast in Optimistic, Conservative and Balanced Perspectives, 2021-2031 16
Figure 4. North America Small Molecule CDMO Market, 2021-2031, $ mn 18
Figure 5. Impact of COVID-19 on Business 21
Figure 6. Primary Drivers and Impact Factors of North America Small Molecule CDMO Market 23
Figure 7. Primary Restraints and Impact Factors of North America Small Molecule CDMO Market 27
Figure 8. Investment Opportunity Analysis 31
Figure 9. Porter’s Fiver Forces Analysis of North America Small Molecule CDMO Market 34
Figure 10. Breakdown of North America Small Molecule CDMO Market by Product Type, 2021-2031, % of Revenue 39
Figure 11. North America Addressable Market Cap in 2022-2031 by Product Type, Value ($ mn) and Share (%) 39
Figure 12. North America Small Molecule CDMO Market by Product Type: Active Pharmaceutical Ingredients (API), 2021-2031, $ mn 40
Figure 13. North America Small Molecule CDMO Market by API: Branded Drugs, 2021-2031, $ mn 41
Figure 14. North America Small Molecule CDMO Market by API: Generic Drugs, 2021-2031, $ mn 42
Figure 15. North America Small Molecule CDMO Market by Product Type: Finished Dosage Formulations (FDF), 2021-2031, $ mn 43
Figure 16. North America Small Molecule CDMO Market by FDF: Oral Solid Drugs, 2021-2031, $ mn 45
Figure 17. North America Small Molecule CDMO Market by FDF: Injectable Drugs, 2021-2031, $ mn 46
Figure 18. North America Small Molecule CDMO Market by FDF: Semi-solid or Liquid Drugs, 2021-2031, $ mn 47
Figure 19. North America Small Molecule CDMO Market by FDF: Other FDFs, 2021-2031, $ mn 48
Figure 20. Breakdown of North America Small Molecule CDMO Market by Service Type, 2021-2031, % of Sales Revenue 50
Figure 21. North America Addressable Market Cap in 2022-2031 by Service Type, Value ($ mn) and Share (%) 50
Figure 22. North America Small Molecule CDMO Market by Service Type: Preclinical Use, 2021-2031, $ mn 51
Figure 23. North America Small Molecule CDMO Market by Service Type: Clinical Use, 2021-2031, $ mn 52
Figure 24. North America Small Molecule CDMO Market by Clinical Use: Phase I, 2021-2031, $ mn 54
Figure 25. North America Small Molecule CDMO Market by Clinical Use: Phase II, 2021-2031, $ mn 55
Figure 26. North America Small Molecule CDMO Market by Clinical Use: Phase III, 2021-2031, $ mn 56
Figure 27. North America Small Molecule CDMO Market by Clinical Use: Phase IV, 2021-2031, $ mn 57
Figure 28. North America Small Molecule CDMO Market by Service Type: Commercial Use, 2021-2031, $ mn 58
Figure 29. Breakdown of North America Small Molecule CDMO Market by Customer Type, 2021-2031, % of Sales Revenue 60
Figure 30. North America Addressable Market Cap in 2022-2031 by Customer Type, Value ($ mn) and Share (%) 60
Figure 31. North America Small Molecule CDMO Market by Customer Type: Pharmaceutical Firms, 2021-2031, $ mn 61
Figure 32. North America Small Molecule CDMO Market by Customer Type: Biotechnology Firms, 2021-2031, $ mn 62
Figure 33. Breakdown of North America Small Molecule CDMO Market by Therapeutic Area, 2021-2031, % of Revenue 64
Figure 34. North America Addressable Market Cap in 2022-2031 by Therapeutic Area, Value ($ mn) and Share (%) 64
Figure 35. North America Small Molecule CDMO Market by Therapeutic Area: Infectious Diseases, 2021-2031, $ mn 65
Figure 36. North America Small Molecule CDMO Market by Therapeutic Area: Oncology, 2021-2031, $ mn 66
Figure 37. North America Small Molecule CDMO Market by Therapeutic Area: Ophthalmology, 2021-2031, $ mn 67
Figure 38. North America Small Molecule CDMO Market by Therapeutic Area: Cardiovascular Disorders, 2021-2031, $ mn 68
Figure 39. North America Small Molecule CDMO Market by Therapeutic Area: Central Nervous System, 2021-2031, $ mn 69
Figure 40. North America Small Molecule CDMO Market by Therapeutic Area: Respiratory Disorders, 2021-2031, $ mn 70
Figure 41. North America Small Molecule CDMO Market by Therapeutic Area: Metabolic Diseases, 2021-2031, $ mn 71
Figure 42. North America Small Molecule CDMO Market by Therapeutic Area: Other Therapeutic Areas, 2021-2031, $ mn 72
Figure 43. Breakdown of North America Small Molecule CDMO Market by Country, 2021 and 2031, % of Revenue 74
Figure 44. Contribution to North America 2022-2031 Cumulative Market by Country, Value ($ mn) and Share (%) 75
Figure 45. U.S. Small Molecule CDMO Market, 2021-2031, $ mn 77
Figure 46. Canada Small Molecule CDMO Market, 2021-2031, $ mn 79
Figure 47. Small Molecule CDMO Market in Mexico, 2021-2031, $ mn 81
Figure 48. Growth Stage of North America Small Molecule CDMO Industry over the Forecast Period 83
Table 1. Snapshot of North America Small Molecule CDMO Market in Balanced Perspective, 2021-2031 17
Table 2. World Economic Outlook, 2021-2031 20
Table 3. Worldwide Total Number of Registered Clinical Trials 26
Table 4. Main Product Trends and Market Opportunities in North America Small Molecule CDMO Market 30
Table 5. North America Small Molecule CDMO Market by Product Type, 2021-2031, $ mn 38
Table 6. North America Small Molecule CDMO Market: API by Type, 2021-2031, $ mn 40
Table 7. North America Small Molecule CDMO Market: FDF by Type, 2021-2031, $ mn 44
Table 8. North America Small Molecule CDMO Market by Service Type, 2021-2031, $ mn 49
Table 9. North America Small Molecule CDMO Market: Clinical Use by Type, 2021-2031, $ mn 53
Table 10. North America Small Molecule CDMO Market by Customer Type, 2021-2031, $ mn 59
Table 11. North America Small Molecule CDMO Market by Therapeutic Area, 2021-2031, $ mn 63
Table 12. North America Small Molecule CDMO Market by Country, 2021-2031, $ mn 74
Table 13. U.S. Small Molecule CDMO Market by Product Type, 2021-2031, $ mn 78
Table 14. U.S. Small Molecule CDMO Market by Service Type, 2021-2031, $ mn 78
Table 15. U.S. Small Molecule CDMO Market by Therapeutic Area, 2021-2031, $ mn 78
Table 16. Canada Small Molecule CDMO Market by Product Type, 2021-2031, $ mn 80
Table 17. Canada Small Molecule CDMO Market by Service Type, 2021-2031, $ mn 80
Table 18. Canada Small Molecule CDMO Market by Therapeutic Area, 2021-2031, $ mn 80
Table 19. Mexico Small Molecule CDMO Market by Product Type, 2021-2031, $ mn 82
Table 20. Mexico Small Molecule CDMO Market by Service Type, 2021-2031, $ mn 82
Table 21. Mexico Small Molecule CDMO Market by Therapeutic Area, 2021-2031, $ mn 82
Table 22. Boehringer Ingelheim: Company Snapshot 87
Table 23. Boehringer Ingelheim: Business Segmentation 88
Table 24. Boehringer Ingelheim: Product Portfolio 88
Related Reports
Allows one individual to access the purchased report Read More
Allows all employees of an organization to access the purchased report. Internal sharing only Read More
Allows all employees of an organization to access the purchased report. It also permits the use of up to 4 paragraphs or 1 page of the report externally in whitepapers, press releases, and marketing collateral Read More
Safe and Secure SSL Encrypted
Quick Contacts
Want to customize this report?
We offer 10% Free Customization at the time of purchase
Get Free Customization
Trusted Partners
Budget constraints? Get in touch with us for special pricing
Request DiscountOrder Detail
- Order Placed (27 July, 2024)
- Notify To Team (27 July, 2024)
- Report updation (28 July, 2024)
- Report Quality Check (28 July, 2024)
- Report Dispatch (29 July, 2024)
- Hard Copy
Recently Viewed Products
North America Small Molecule Contract Development and Manufacturing Organization (CDMO) Market 2021-2031 by Product Type (API, FDF), Service Type (Preclinical, Clinical, Commercial), Customer Type (Pharmaceutical Firms, Biotechnology Firms), Therapeutic Area (Infectious Diseases, Oncology, Ophthalmology, Cardiovascular Disorders, Central Nervous System, Respiratory Disorders, Metabolic Diseases), and Country: Trend Forecast and Growth Opportunity
We are friendly and approachable, give us a call.